Low- versus high-dose trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia pneumonia
Open Access
- 15 April 2025
- journal article
- research article
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e95
Abstract
Objective: To compare outcomes of patients treated with low-dose (LD) versus high-dose (HD) trimethoprim-sulfamethoxazole (TMP-SMX) for Stenotrophomonas maltophilia pneumonia. Design: Retrospective cohort study. Setting: Large academic tertiary-care center. Patients: Hospitalized adult patients who received at least 8 mg/kg/day of TMP-SMX for at least 96 hours for treatment of S. maltophilia pneumonia between October 2012 and September 2022. Patients were included if they were diagnosed with pneumonia based on clinical and radiographic findings at the time of initiation of antibiotics. Methods: The primary outcome was clinical success at the end of therapy among patients treated with LD (8–12 mg/kg/day) versus HD (>12 mg/kg/day) TMP-SMX. Secondary outcomes included microbiological success, all-cause and infection-related inpatient mortality, infection recurrence, development of TMP-SMX resistance, and incidence of acute kidney injury (AKI) and hyperkalemia. Results: 95 patients were included (LD, n = 20 versus HD, n = 75). There was no difference in the primary outcome of clinical success at the end of therapy between groups (LD 57% versus HD 65%, P = 0.53). Secondary outcomes, including inpatient infection-related mortality (P = 0.56), AKI (P = 0.61), and hyperkalemia (P = 0.34) also did not differ significantly between the LD and HD groups. Conclusions: No differences in clinical success or adverse events were observed in patients with S. maltophilia pneumonia treated with either LD or HD TMP-SMX.Keywords
This publication has 24 references indexed in Scilit:
- Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative InfectionsClinical Infectious Diseases, 2024
- Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-ResistantAcinetobacter baumannii, andStenotrophomonas maltophiliaInfectionsClinical Infectious Diseases, 2021
- 1491. Standard- vs. High-dose Trimethoprim-Sulfamethoxazole for Stenotrophomonas maltophilia pneumoniaOpen Forum Infectious Diseases, 2020
- Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment ofStenotrophomonas maltophiliainfectionsJournal of Antimicrobial Chemotherapy, 2016
- Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2009
- Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997–2004European Journal of Clinical Microbiology & Infectious Diseases, 2007
- Attributable Mortality ofStenotrophomonas maltophiliaBacteremiaClinical Infectious Diseases, 2002
- Bacteremia Due to Stenotrophomonas (Xanthomonas) maltophilia: A Prospective, Multicenter Study of 91 EpisodesClinical Infectious Diseases, 1996
- Clinical features of Stenotrophomonas maltophilia pneumonia in immunocompromised patientsRespiratory Medicine, 1996
- Sulphamethoxazole/trimethoprim: Pharmacokinetic studies in patients with chronic renal failureEuropean Journal of Clinical Pharmacology, 1972